Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.   (Currently amended) A modified antibody of class IgG comprising a variable region from daclizumab and a heavy chain constant region, wherein at least amino acid ~~residues~~ residue 250, EU numbering, is glutamic acid or glutamine and amino acid residue 428, EU numbering, is leucine or phenylalanine ~~from the heavy chain constant region are different from the residues present in an unmodified class IgG antibody~~, wherein the FcRn binding affinity and/or serum half-life of said modified antibody is altered relative to that of the unmodified antibody, and wherein ~~amino acid residues are numbered by the EU numbering system~~ the variable region from daclizumab comprises a mature light chain variable region of SEQ ID NO:118 and a mature heavy chain variable region of SEQ ID NO: 122.

2.   (Currently amended) The modified antibody according to Claim 1, wherein said heavy chain constant region is ~~from daclizumab~~ that of IgG1.

3.   (Currently amended) An antibody comprising a variable region from daclizumab and a heavy chain constant region substantially identical to that of a naturally occurring class IgG antibody wherein

at least amino acid ~~residues 250 and 428 from the heavy chain constant region are~~ residue 250, EU numbering, is glutamic acid or glutamine and amino acid residue 428, EU numbering, is leucine or phenylalanine and different from ~~that~~ residues 250 and 428 as present in the naturally occurring class IgG antibody, ~~wherein~~

the FcRn binding affinity and/or serum half-life of said antibody is altered relative to the naturally occurring antibody, and ~~wherein amino acid residues are numbered by the EU numbering system~~

Appl. No. 10/822,300
Amdt. dated December 7, 2006
Submission with a Request under 37 CFR 1.114
Examining Group 1644

PATENT

the variable region from daclizumab comprises a mature light chain variable region of SEQ ID NO:118 and a mature heavy chain variable region of SEQ ID NO: 122.

4.   (Previously presented) The antibody according to Claim 3 wherein said heavy chain constant region is from daclizumab.

5.   (Currently amended) [[The]] An antibody comprising a variable region from daclizumab and a heavy chain constant region according to Claim 3, wherein:

(a)   ~~said~~ amino acid residue 250 from the heavy chain constant region is glutamic acid or glutamine; ~~or~~

(b)   ~~said~~ amino acid residue 428 from the heavy chain constant region is phenylalanine or leucine; and

(c)   the variable region from daclizumab comprises a mature light chain variable region of SEQ ID NO:118 and a mature heavy chain variable region of SEQ ID NO: 122.

6.   (Original) The antibody according to Claim 3, wherein said amino acid residue 250 from the heavy chain constant region is glutamine.

7.   (Original) The antibody according to Claim 3, wherein said amino acid residue 428 from the heavy chain constant region is leucine.

8.   (Original) The antibody according to Claim 3, wherein:

said amino acid residue 250 from the heavy chain constant region is glutamic acid and said amino acid residue 428 from the heavy chain constant region is phenylalanine;

said amino acid residue 250 from the heavy chain constant region is glutamine and said amino acid residue 428 from the heavy chain constant region is phenylalanine; or

said amino acid residue 250 from the heavy chain constant region is glutamine and said amino acid residue 428 from the heavy chain constant region is leucine.

9-12.   (canceled)

Appl. No. 10/822,300
Amdt. dated December 7, 2006
Submission with a Request under 37 CFR 1.114
Examining Group 1644

PATENT

13.   (Previously presented) A modified antibody of Claim 1 with an *in vivo* clearance at least about 1.3-fold lower than that of the corresponding unmodified class IgG antibody.

14-15. (cancel)

16.   (Currently amended) A modified therapeutic antibody comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence selected from SEQ ID NOs: ~~119-128~~ 120, 122-123, 125, and 127-128.

17-27. (canceled)

28.   (Previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 122.

29.   (Previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 127.

30.   (Previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 123.

31.   (Previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 128.

32.   (Previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 120.

Appl. No. 10/822,300
Amdt. dated December 7, 2006
Submission with a Request under 37 CFR 1.114
Examining Group 1644

PATENT

     33.   (Previously presented) The modified therapeutic antibody of Claim 16 comprising a light chain amino acid sequence of SEQ ID NO: 118 and a heavy chain amino acid sequence of SEQ ID NO: 125.

     34-37. (canceled)

     38.   (Previously presented) The modified antibody of Claim 1 wherein said class IgG antibody is a human IgG1.

     39.   (Previously presented) The modified antibody of Claim 1 wherein said class IgG antibody is a human IgG2M3.

     40.   (Currently amended) The ~~modified~~ antibody of Claim 3 wherein said class IgG antibody is a human IgG1.

     41.   (Currently amended) The ~~modified~~ antibody of Claim 3 wherein said class IgG antibody is a human IgG2M3.